Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children

R. B. Belshe, R. A. Karron, F. K. Newman, E. L. Anderson, S. L. Nugent, M. Steinhoff, M. L. Clements, M. H. Wilson, S. L. Hall, E. L. Tierney, B. R. Murphy

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Cold passage 18 (CP18) parainfluenza virus type 3 (PIV-3) vaccine was evaluated in a double-blind, randomized, placebo-controlled study of 95 infants and young children. None of 19 seropositive older children 41 to 124 months old became infected when 106 50% tissue culture infective doses (TCID50) of vaccine virus was administered intranasally. Two of nine and seven of twenty-four young seropositive children given 105 or 106 TCID50 of CP18 PIV-3, respectively, became infected. Each of four seronegative young children became infected, as indicated by virus shedding and antibody response, when given 106 TCID50 of CP18 PIV-3 intranasally. Illness was not observed in seropositive children. Two of the four seronegative children developed a mild illness characterized by rhinorrhea and wheezing on auscultation; none had fever. In one case, vaccine virus spread from a vaccinee to a sibling control but did not cause illness. The vaccine is attenuated relative to wild-type PIV-3, but additional attenuation will be required to achieve a satisfactory PIV-3 vaccine.

Original languageEnglish (US)
Pages (from-to)2064-2070
Number of pages7
JournalJournal of clinical microbiology
Issue number8
StatePublished - 1992
Externally publishedYes

ASJC Scopus subject areas

  • Microbiology (medical)


Dive into the research topics of 'Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children'. Together they form a unique fingerprint.

Cite this